The aim of this review is to put forth the notion that the immunology of cord blood transplants for regenerative applications has to be viewed differently from the perspective and the practice of cord blood transplants for hematopoietic reconstitution.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1796850/
Neil H Riordan, Kyle Chan, Annette M Marleau, and Thomas E Ichim
Few methods are available to regenerate articular cartilage defects in patients with osteoarthritis. We aimed to assess the safety and efficacy of articular cartilage regeneration by a novel medicinal product composed of allogeneic human umbilical cord blood‐derived mesenchymal regenerative medicines (hUCB‐MSCs). Patients with Kellgren‐Lawrence grade 3 osteoarthritis and International Cartilage Repair Society (ICRS) grade 4 cartilage defects were enrolled in this clinical trial. The regenerative medicine‐based medicinal product (a composite of culture‐expanded allogeneic hUCB‐MSCs and hyaluronic acid hydrogel [Cartistem]) was applied to the lesion site.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442809/